Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 19/20 | 0.72 |
| ▸ | JAK3 | P52333 | 9/20 | 0.72 |
| ▸ | JAK2 | O60674 | 10/20 | 0.71 |
| ▸ | TYK2 | P29597 | 5/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612667 | 1.00 | JAK1 (0.72) | JAK1JAK3JAK2TYK2 | |
| Hydrochloric Acid SCHEMBL15970187 | 0.99 | JAK1 (0.71) | JAK1JAK3JAK2TYK2 | |
| Hydrochloric Acid SCHEMBL15970189 | 0.99 | JAK1 (0.71) | JAK1JAK3JAK2TYK2 | |
| Hydrochloric Acid SCHEMBL15970568 | 0.99 | JAK1 (0.71) | JAK1JAK3JAK2TYK2 | |
| Hydrochloric Acid SCHEMBL15970467 | 0.89 | JAK1 (0.70) | JAK1JAK3JAK2TYK2 | |
| Hydrochloric Acid SCHEMBL15970470 | 0.89 | JAK1 (0.70) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL15978535 | 0.89 | JAK3 (0.81) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL22001726 | 0.87 | JAK1 (0.80) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL29517918 | 0.87 | JAK1 (0.80) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL3537764 | 0.87 | JAK3 (0.79) | JAK1JAK3JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735444-A1 | BENZYL (3-(METHYL(7H-PYRROLO[2,3-D]PYRIMIDIN-4YL)AMINO)CYCLOBUTYL) CARBAMATE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF ABROCITINIB | Moehs Ibérica, S.L. (ES) | 2026-05-06 | — | — | EP | disclosed |
| EP-3817810-B1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3- D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4157845-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025003177-A1 | BENZYL (3-(METHYL(7H-PYRROLO[2,3-D]PYRIMIDIN-4YL)AMINO)CYCLOBUTYL) CARBAMATE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF ABROCITINIB | MOEHS IBERICA, S.L. (ES) | 2025-01-02 | — | — | WO | disclosed |
| US-12018031-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | PFIZER INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018031-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | PFIZER INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018031-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | PFIZER INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230219963-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219963-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4157845-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | Pfizer Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-112384282-A | Process for producing pyrrolo [2,3-d ] pyrimidine compound, intermediate and use thereof | 辉瑞公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20210009601-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210009601-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10815240-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10815240-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200123159-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2020-04-23 | — | — | US | disclosed |
| US-20200123159-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2020008391-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3- D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2020-01-09 | — | — | WO | disclosed |
| WO-2020008391-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3- D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2020-01-09 | — | — | WO | disclosed |
| WO-2014128591-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) | PFIZER INC. (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009601-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | TPMT, DHPS, DPYD | JAK1 150/4885JAK3 223/4885JAK2 837/4885 |
| US-12018031-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | TPMT, DHPS, DPYD | JAK1 150/4885JAK3 223/4885JAK2 837/4885 |
| US-20230219963-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | JAK1 2/4885JAK3 1/4885JAK2 3/4885 |
| US-20200123159-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | TPMT, DHPS, DPYD | JAK1 150/4885JAK3 223/4885JAK2 837/4885 |
| US-10815240-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | TPMT, DHPS, DPYD | JAK1 150/4885JAK3 223/4885JAK2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.